RecruitingNot ApplicableNCT05346367

Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases


Sponsor

Haaglanden Medical Centre

Enrollment

130 participants

Start Date

Jul 18, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases. The current standard of stereotactic radiotherapy (SRT) in one or three fractions is compared to fractionated stereotactic radiotherapy (fSRT) in five fractions.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age ≥ 18 years
  • At least one brain metastasis of large cell cancer suitable for SRT
  • Karnofsky Performance Status ≥ 70
  • Ability to provide written informed consent
  • New brain metastases during follow-up after surgery allowed (when outside of resection cavity area)
  • New brain metastases during follow-up after previous SRT allowed (when outside of previous irradiation field)

Exclusion Criteria5

  • Contra-indication for MRI scan
  • Primary tumor of small cell lung cancer, germinoma or lymphoma
  • Prior whole brain radiotherapy or SRT on the current target brain metastases (in field re-irradiation)
  • Presence of leptomeningeal metastases
  • Previous inclusion in the SAFESTEREO study

Interventions

RADIATIONSRT

SRT

RADIATIONfSRT

fSRT


Locations(1)

Haaglanden Medisch Centrum

Leidschendam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05346367


Related Trials